4.7 Article

Inhibition of SARS-CoV replication by siRNA

Journal

ANTIVIRAL RESEARCH
Volume 65, Issue 1, Pages 45-48

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2004.09.005

Keywords

SARS-CoV; siRNA; spike protein; antiviral agent

Ask authors/readers for more resources

Serious outbreaks of severe acute respiratory syndrome (SARS), caused by the newly discovered coronavirus SARS-CoV occurred between late 2002 and early 2003 and there is an urgent need for effective antiviral agents. RNA interference in animals and post-transcriptional gene silencing plants is mediated by small double-stranded RNA molecules named small interfering RNA (siRNA). Recently, siRNA-induced RNA interference(RNAi) may provide a new approach to therapy for pathogenic viruses, e.g. HIV and HCV In this study, the silencing potential of seven synthetic siRNAs against SARS-CoV leader, TRS, 3'-UTR and Spike coding sequence have been applied to explore, the possibility for prevention of SARS-CoV infection. We demonstrate that siRNAs directed against Spike sequences and the 3'-UTR can inhibit the replication of SARS-CoV in Vero-E6 cells. and holds out promise for the development of an effective antiviral agent against SARS-CoV (C) 2004 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available